A phase II study to evaluate safety and efficacy of combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma

Trial Profile

A phase II study to evaluate safety and efficacy of combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Sep 2015

At a glance

  • Drugs Aldesleukin (Primary) ; Ipilimumab (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Acronyms i i i
  • Most Recent Events

    • 19 Sep 2015 Status changed from planning to completed, as reported by European Clinical Trials Database (EudraCT2010-019033-98)
    • 06 Jul 2015 New trial record
    • 02 Jun 2015 Based on results of a phase I trial (see trial profile 700222282), investigators at the University of Utah are planning to conduct this phase II trial of intratumoural ipilimumab and aldesleukin in conjunction with systemic immunotherapy, according to an abstract presented at ASCO 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top